A systematic review and meta-analysis by George et al. demonstrated that treatment with anti-CTLA-4 mAbs increases the incidence of pancreatitis compared to treatment with anti-PD-1 mAbs, while an additive increase in incidence of pancreatitis is observed with a combination of anti-CTLA-4 and anti-PD-1 mAbs compared to either anti-CTLA-4 or anti-PD-1 mAbs as monotherapy [83]. Here, CTLA4 is linked to pancreatitis.